Invion
- Short interest
- 0.01%
- +0.01 pp 30d
- as of 11 Feb 2025
- Reported shorts
- 8.5K
- Shares on issue
- 70.356M
Invion (IVX) Short Interest
Invion (ASX:IVX) had 0.01% of shares reported as short positions as of 11 Feb 2025, representing 8,518 shares. Invion operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Invion
Invion is a clinical-stage pharmaceutical company specializing in the development of PhotoDynamic Therapy (PDT) for cancer treatment. The company holds exclusive rights to the Photosoft technology in various regions, aiming to improve cancer treatment efficacy with minimal side effects.
Company profile →Invion (ASX:IVX) has 0.01% of its shares on issue reported as short positions as of 11 Feb 2025, or about 8,518 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 1.02% in June 2013. IVX is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads IVX today
- Zanger BreakoutWatchScore 19rank 1311 of 1942
- CAN SLIMNot a candidate
- Minervini Trend TemplateNot a candidate
- Crowded-Short BreakoutWatchScore 10rank 972 of 1502
- Quality compoundersNot a candidate
Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
IVX fundamentals
In the year to 30 Jun 2026, Invion (ASX:IVX) recorded revenue of A$384.7K and a net loss after tax of A$5.6M. A year earlier it recorded revenue of A$0 and a net loss after tax of A$8.8M. Net margin −1,464.2% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit) and Yahoo Finance, as at 14 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest IVX news
All news- Proposed issue of securities - IVX
asx · 28 Sept 2026
- Director Loans
asx · 28 Sept 2026
- Appendix 4G and Corporate Governance Statement
asx · 25 Aug 2026
Company details
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss IVX
Start a research thread or post the first pulse update